Therapy Watch appoints new Associate Director
Research Partnership is delighted to welcome Mark Hollis who has joined the Therapy Watch team in London.
Mark has 8 years’ experience in syndicated healthcare, and previously worked in the Market Prognosis team at IQVIA (IMS Health), where he led field work, analytics, forecasting and report writing for the Middle East and North Africa region.
Sabera Hyderally appointed Head of MedTech North America
Research Partnership is delighted to welcome Sabera Hyderally who has joined the company’s US headquarters in Philadelphia.
Sabera has over 20 years’ experience in market research, specifically on the agency side. Most recently she was at Lieberman where for the last 7 years she held the position of Executive Vice President of Health.
Full speed ahead: Unlock the full potential of your brand tracking
You know that you need to conduct regular research to track the performance of your brand. But is your brand tracking delivering the insights your stakeholders need?
If you’re setting up a new brand tracker or you’ve already got one but you’re not sure it’s performing at its best, this webcast is for you.
Dan Coffin joins London Headquarters as Director
Research Partnership is delighted to welcome Dan Coffin who has joined the company’s global head office in London
Dan Coffin joins Research Partnership as Director for the EU region. Dan has over 18 years’ experience in the pharmaceutical sector, with particular interest in digital therapy and the growing health-tech arena. Dan brings experience from the agency side, strengthened by client-side roles at Roche and Johnson & Johnson. Most recently, Dan was employed at Illuminas where he established and ran their healthcare market research arm. He is an active industry contributor and has been a BHBIA Board director since 2013.
How scenario testing helped assess demand for a brand launch in the fragmented NSCLC market
Our client was developing a new drug aimed at first line NSCLC patients. Ahead of its launch they wanted to assess likely uptake in an already fragmented market space led by established 1st generation tyrosine kinase inhibitors (TKIs). There were several scenarios that the client wanted to test, including impact of launch order and the impact of future 3rd generation TKIs on the drug’s market potential. The research was complicated by the fact that both the clients (and likely key future competitors’), profile was as yet unknown – the research therefore needed to assess likely share while taking account of multiple moving parts.